Results 291 to 300 of about 105,968 (369)

Association between the AHA life’s essential 8 and prediabetes/diabetes: a cross-sectional NHANES study [PDF]

Wei Xu, Yuntao Feng, Guzalnur Abdullah, Ling Li, Ping Fang, Sijing Tang, Huanhuan Yang, Dehong Kong, Hemin Huang, Yang Wang, Ying Xue   +10 more
openalex   +1 more source

An open‐label study on ulotaront's effects on insulin‐glucose regulation in schizophrenia patients with metabolic syndrome and prediabetes: Part I

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 103-111, January 2026.
Abstract Aims Ulotaront is an investigational trace amine‐associated receptor 1 (TAAR1) agonist demonstrated to slow gastric emptying in schizophrenia patients with metabolic syndrome (MetSyn) and prediabetes type 2. Here we evaluate the effects of ulotaront on glucose‐insulin dynamics in schizophrenia patients with MetSyn and prediabetes.
Snezana Milanovic, Robert Lew, Kuangnan Xiong, Emily Casavant, Gerard Galluppi, Yu‐Luan Chen, Yongquan Lai, Manu Chakravarthy, Clay Dehn, Kenneth Koblan, Seth C. Hopkins   +10 more
wiley   +1 more source

Stratifying high-risk prediabetes clusters using blood-based epigenetic markers. [PDF]

Biomark Res
Singh A, Schwartzenberg RJ, Wagner R, Sandforth L, Sandforth A, Jähnert M, Ganslmeier M, Kabisch S, Perakakis N, Preißl H, Fritsche A, Stefan N, Walter D, Ouni M, Birkenfeld AL, Schürmann A.   +15 more
europepmc   +1 more source

Influence of T2DM and prediabetes on blood DC subsets and function in subjects with periodontitis

, 2019
Mariana de Sousa Rabelo, Ahmed El‐Awady, Adriana Moura Foz, Giovane Hisse Gomes, Mythilpriya Rajendran, Mohamed M. Meghil, Scott Lowry, Giuseppe Alexandre Romito, Christopher W. Cutler, Cristiano Susin   +9 more
openalex   +2 more sources

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial (SYNCHRONIZE™‐1)

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 337-346, January 2026.
Abstract Aims Survodutide, a novel glucagon receptor and glucagon‐like peptide‐1 (GLP‐1) receptor dual agonist, elicited significant weight loss in a phase 2 trial in individuals with obesity without type 2 diabetes (T2D). Two multinational phase 3 trials are investigating survodutide for obesity management in individuals with or without T2D. We report
Carel W. le Roux, Sean Wharton, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source

Impact of skeletal muscle mass index on glycemic progression and remission in Chinese adults with prediabetes: a nationwide cohort study. [PDF]

Eur J Med Res
Wan J, Huang X, Zou Y, Sheng G, Xie G, Zhang N.   +5 more
europepmc   +1 more source

Appetite Regulation and Allostatic Load Across Prediabetes Phenotypes. [PDF]

Nutrients
Malin SK, Heiston EM.
europepmc   +1 more source

Comments: "Effect of long-term negative energy on appetite hormone levels in individuals with prediabetes and diabetes"

Sami A. Gabr
openalex   +1 more source

Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 83-93, January 2026.
Abstract Aims Retatrutide, a novel synthetic molecule, is a triple agonist activating the glucose‐dependent insulinotropic polypeptide, glucagon‐like peptide‐1 and glucagon receptors. The TRIUMPH clinical development program evaluates its safety and efficacy concurrently for the treatment of obesity and two related complications—obstructive sleep apnea
Kathryn Giblin, Lee M. Kaplan, Virend K. Somers, Carel W. Le Roux, David J. Hunter, Qiwei Wu, Amy Lalonde, Nadia Ahmad, Mary Angelyn Bethel   +8 more
wiley   +1 more source

Global epidemiology of diabetes and prediabetes in lean or non-obese patients with NAFLD: a systematic review and meta-analysis. [PDF]

Ann Med
Li YY, Yu Y, Jing HB, Gu YH, Zhang HF, Bao WP, Liu C, Cao L, Fan YF.   +8 more
europepmc   +1 more source